• No results found

Clinical pharmacology of the tyrosine kinase inhibitors imatinib and sunitinib Erp, P.H. van

N/A
N/A
Protected

Academic year: 2021

Share "Clinical pharmacology of the tyrosine kinase inhibitors imatinib and sunitinib Erp, P.H. van"

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Clinical pharmacology of the tyrosine kinase inhibitors imatinib and sunitinib

Erp, P.H. van

Citation

Erp, P. H. van. (2009, December 16). Clinical pharmacology of the tyrosine kinase inhibitors imatinib and sunitinib. Retrieved from https://hdl.handle.net/1887/14515

Version: Corrected Publisher’s Version

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden Downloaded

from: https://hdl.handle.net/1887/14515

Note: To cite this publication please use the final published version (if applicable).

(2)

C linical Pharmac ology of the Tyr osine K inase Inhibit ors Ima tinib and Sunitinib N ielk a van Erp

Voor het bijwonen van de openbare verdediging van het

proefschrift

Clinical Pharmacology of the Tyrosine Kinase Inhibitors

Imatinib and Sunitinib

Op woensdag 16 december 2009 Om 13:45 uur

In de Senaatskamer van het Academiegebouw,

Rapenburg 73, te Leiden

Het bijwonen van de promotie is gezien het geringe aantal beschikbare

paatsen, alleen mogelijk op vertoon van een bewijs van toegang. Dit is aan

te vragen bij het secretariaat van de afdeling Klinische Farmacie en

Toxicologie (tel 071-5262790).

U wordt erop geattendeerd dat het moeilijk en tijdrovend is om in de buurt

van het Academiegebouw te parkeren.

Paranimfen Anthe Zandvliet anthezandvliet@gmail.com

020 8902901 Jan Pander j.pander@live.nl

06 41276096

Nielka van Erp

Clinical Pharmacology of the Tyrosine Kinase Inhibitors

Imatinib and Sunitinib Uitnodiging

Referenties

GERELATEERDE DOCUMENTEN

The study was designed to determine the relationship between CYP3A4 activity and sunitinib exposure in cancer patients and additionally to evaluate the effect of sunitinib on

The aim of the present study is to identify genetic markers in sunitinib disposition, metabolism, and mechanism of action that predispose for development of common sunitinib

Next, a final model was developed by the introduction of a grapefruit juice effect on the relative bioavailability of sunitinib, resulting in an effect on the apparent clearance

Both mitotane exposed patients showed highly induced CYP3A4 activity resulting in decreased sunitinib, and midazolam exposure (including increased 1-hydroxy-midazolam exposure)

The most abundant fura- nocoumarins present in grapefruit juice are bergamottin (BG) and 6’,7’-dihydroxybergamottin (DHB). A complicating factor is that among grapefruit juices

Recently, a correlation was observed between clinical effect in CML (defined as major molecular response and complete cytogenetic response) and a minimal trough level of

It appears that midazolam exposure relates well to sunitinib exposure as well as sunitinib trough levels and explains a large part of the interpatient variability in

Sunitinib dalspiegel en sunitinib blootstelling zijn sterk gecorreleerd waardoor in vervolgonderzoek de sunitinib dalspiegel in plaats van de vele male intensievere volledige